633 related articles for article (PubMed ID: 9390264)
21. Structure-based thermodynamic analysis of HIV-1 protease inhibitors.
Bardi JS; Luque I; Freire E
Biochemistry; 1997 Jun; 36(22):6588-96. PubMed ID: 9184138
[TBL] [Abstract][Full Text] [Related]
22. Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 3. The free energy contribution of structural water molecules in HIV-1 protease complexes.
Fornabaio M; Spyrakis F; Mozzarelli A; Cozzini P; Abraham DJ; Kellogg GE
J Med Chem; 2004 Aug; 47(18):4507-16. PubMed ID: 15317462
[TBL] [Abstract][Full Text] [Related]
23. Absolute and relative binding free energy calculations of the interaction of biotin and its analogs with streptavidin using molecular dynamics/free energy perturbation approaches.
Miyamoto S; Kollman PA
Proteins; 1993 Jul; 16(3):226-45. PubMed ID: 8346190
[TBL] [Abstract][Full Text] [Related]
24. Molecular dynamic and free energy studies of primary resistance mutations in HIV-1 protease-ritonavir complexes.
Aruksakunwong O; Wolschann P; Hannongbua S; Sompornpisut P
J Chem Inf Model; 2006; 46(5):2085-92. PubMed ID: 16995739
[TBL] [Abstract][Full Text] [Related]
25. PEARLS: program for energetic analysis of receptor-ligand system.
Han LY; Lin HH; Li ZR; Zheng CJ; Cao ZW; Xie B; Chen YZ
J Chem Inf Model; 2006; 46(1):445-50. PubMed ID: 16426079
[TBL] [Abstract][Full Text] [Related]
26. Enthalpy-Entropy Compensation upon Molecular Conformational Changes.
Ahmad M; Helms V; Lengauer T; Kalinina OV
J Chem Theory Comput; 2015 Apr; 11(4):1410-8. PubMed ID: 26574352
[TBL] [Abstract][Full Text] [Related]
27. Empirical free energy as a target function in docking and design: application to HIV-1 protease inhibitors.
King BL; Vajda S; DeLisi C
FEBS Lett; 1996 Apr; 384(1):87-91. PubMed ID: 8797810
[TBL] [Abstract][Full Text] [Related]
28. Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors.
Wittayanarakul K; Hannongbua S; Feig M
J Comput Chem; 2008 Apr; 29(5):673-85. PubMed ID: 17849388
[TBL] [Abstract][Full Text] [Related]
29. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
Cihlar T; He GX; Liu X; Chen JM; Hatada M; Swaminathan S; McDermott MJ; Yang ZY; Mulato AS; Chen X; Leavitt SA; Stray KM; Lee WA
J Mol Biol; 2006 Oct; 363(3):635-47. PubMed ID: 16979654
[TBL] [Abstract][Full Text] [Related]
30. Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model.
Wang W; Kollman PA
J Mol Biol; 2000 Nov; 303(4):567-82. PubMed ID: 11054292
[TBL] [Abstract][Full Text] [Related]
31. The thermodynamics of protein-ligand interaction and solvation: insights for ligand design.
Olsson TS; Williams MA; Pitt WR; Ladbury JE
J Mol Biol; 2008 Dec; 384(4):1002-17. PubMed ID: 18930735
[TBL] [Abstract][Full Text] [Related]
32. Structure-based ligand design by dynamically assembling molecular building blocks at binding site.
Liu H; Duan Z; Luo Q; Shi Y
Proteins; 1999 Sep; 36(4):462-70. PubMed ID: 10450088
[TBL] [Abstract][Full Text] [Related]
33. Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance.
Hou T; Yu R
J Med Chem; 2007 Mar; 50(6):1177-88. PubMed ID: 17300185
[TBL] [Abstract][Full Text] [Related]
34. Conformational analysis of TMC114, a novel HIV-1 protease inhibitor.
Nivesanond K; Peeters A; Lamoen D; Van Alsenoy C
J Chem Inf Model; 2008 Jan; 48(1):99-108. PubMed ID: 18173253
[TBL] [Abstract][Full Text] [Related]
35. Empirical free energy calculations of phage 434 repressor- and cro-DNA complexes support the 'indirect readout' hypothesis of specificity.
Brown LM; Bruccoleri RE; Novotny J
Pac Symp Biocomput; 1998; ():339-48. PubMed ID: 9697194
[TBL] [Abstract][Full Text] [Related]
36. Effect of protein backbone folding on the stability of protein-ligand complexes.
Estrada E; Uriarte E; Vilar S
J Proteome Res; 2006 Jan; 5(1):105-11. PubMed ID: 16396500
[TBL] [Abstract][Full Text] [Related]
37. An approach to rapid estimation of relative binding affinities of enzyme inhibitors: application to peptidomimetic inhibitors of the human immunodeficiency virus type 1 protease.
Viswanadhan VN; Reddy MR; Wlodawer A; Varney MD; Weinstein JN
J Med Chem; 1996 Feb; 39(3):705-12. PubMed ID: 8576913
[TBL] [Abstract][Full Text] [Related]
38. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
39. Molecular dynamics simulations of the three dimensional model of plasmepsin II-peptidic inhibitor complexes.
Pranav Kumar SK; Kulkarni VM
Drug Des Discov; 2001; 17(4):293-313. PubMed ID: 11765133
[TBL] [Abstract][Full Text] [Related]
40. A semiempirical free energy force field with charge-based desolvation.
Huey R; Morris GM; Olson AJ; Goodsell DS
J Comput Chem; 2007 Apr; 28(6):1145-52. PubMed ID: 17274016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
